This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against Chlamydia infections. The compositions comprise Chlamydia sp. antigens and antigen combinations which can be used to immunise against Chlamydia sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.

The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.

Purified Chlamydia major outer membrane protein (MOMP) has been observed to induce protection against genital and respiratory challenge in mice. MOMP contains variable domains that are highly immunogenic and elicit cross-serovar neutralizing monoclonal and polyclonal antibodies and T cell responses in animal and human models. Examples herein provide a method for vaccinating a subject against Chlamydia using a composition that is a recombinant Neisseria porin that contains at least one antigenic variable domain of Chlamydia. The variable domains are inserted into the amino acid sequence of the Neisseria porin at a position encoding a surface-exposed loop of the Neisseria porin. The vaccine further contains an adjuvant that induces a Th1 response greater than a Th2 response.

Purified Chlamydia major outer membrane protein (MOMP) has been observed to induce protection against genital and respiratory challenge in mice. MOMP contains variable domains that are highly immunogenic and elicit cross-serovar neutralizing monoclonal and polyclonal antibodies and T cell responses in animal and human models. Examples herein provide a method for vaccinating a subject against Chlamydia using a composition that is a recombinant Neisseria porin that contains at least one antigenic variable domain of Chlamydia. The variable domains are inserted into the amino acid sequence of the Neisseria porin at a position encoding a surface-exposed loop of the Neisseria porin. The vaccine further contains an adjuvant that induces a Th1 response greater than a Th2 response.

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.

The present invention relates to a method and kit for detecting and diagnosing Chlamydia suis infections in a subject using peptides comprising the amino acid sequence of GTKDASID and/or SQQSSIAS as antigenic determinants.